337 related articles for article (PubMed ID: 22697514)
1. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
Esposito E; Cuzzocrea S
Mini Rev Med Chem; 2013 Feb; 13(2):237-55. PubMed ID: 22697514
[TBL] [Abstract][Full Text] [Related]
2. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals.
Re G; Barbero R; Miolo A; Di Marzo V
Vet J; 2007 Jan; 173(1):21-30. PubMed ID: 16324856
[TBL] [Abstract][Full Text] [Related]
3. N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress.
Mattace Raso G; Simeoli R; Russo R; Santoro A; Pirozzi C; d'Emmanuele di Villa Bianca R; Mitidieri E; Paciello O; Pagano TB; Orefice NS; Meli R; Calignano A
Pharmacol Res; 2013 Oct; 76():67-76. PubMed ID: 23917217
[TBL] [Abstract][Full Text] [Related]
4. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation.
Esposito G; Capoccia E; Turco F; Palumbo I; Lu J; Steardo A; Cuomo R; Sarnelli G; Steardo L
Gut; 2014 Aug; 63(8):1300-12. PubMed ID: 24082036
[TBL] [Abstract][Full Text] [Related]
5. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice.
Ahmad A; Crupi R; Impellizzeri D; Campolo M; Marino A; Esposito E; Cuzzocrea S
Brain Behav Immun; 2012 Nov; 26(8):1310-21. PubMed ID: 22884901
[TBL] [Abstract][Full Text] [Related]
6. Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.
Paterniti I; Impellizzeri D; Crupi R; Morabito R; Campolo M; Esposito E; Cuzzocrea S
J Neuroinflammation; 2013 Feb; 10():20. PubMed ID: 23374874
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems.
Costa B; Conti S; Giagnoni G; Colleoni M
Br J Pharmacol; 2002 Oct; 137(4):413-20. PubMed ID: 12359622
[TBL] [Abstract][Full Text] [Related]
8. Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence.
Coppola M; Mondola R
Med Hypotheses; 2013 Oct; 81(4):619-22. PubMed ID: 23896215
[TBL] [Abstract][Full Text] [Related]
9. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide.
Bettoni I; Comelli F; Colombo A; Bonfanti P; Costa B
CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):34-44. PubMed ID: 23394519
[TBL] [Abstract][Full Text] [Related]
10. The palmitoylethanolamide family: a new class of anti-inflammatory agents?
Lambert DM; Vandevoorde S; Jonsson KO; Fowler CJ
Curr Med Chem; 2002 Mar; 9(6):663-74. PubMed ID: 11945130
[TBL] [Abstract][Full Text] [Related]
11. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia.
D'Agostino G; La Rana G; Russo R; Sasso O; Iacono A; Esposito E; Mattace Raso G; Cuzzocrea S; Loverme J; Piomelli D; Meli R; Calignano A
Eur J Pharmacol; 2009 Jun; 613(1-3):54-9. PubMed ID: 19386271
[TBL] [Abstract][Full Text] [Related]
12. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells.
Cerrato S; Brazis P; della Valle MF; Miolo A; Puigdemont A
Vet Immunol Immunopathol; 2010 Jan; 133(1):9-15. PubMed ID: 19625089
[TBL] [Abstract][Full Text] [Related]
13. Palmitoylethanolamide inhibits rMCP-5 expression by regulating MITF activation in rat chronic granulomatous inflammation.
De Filippis D; Russo A; De Stefano D; Cipriano M; Esposito D; Grassia G; Carnuccio R; Russo G; Iuvone T
Eur J Pharmacol; 2014 Feb; 725():64-9. PubMed ID: 24440533
[TBL] [Abstract][Full Text] [Related]
14. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis.
Gatti A; Lazzari M; Gianfelice V; Di Paolo A; Sabato E; Sabato AF
Pain Med; 2012 Sep; 13(9):1121-30. PubMed ID: 22845893
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats.
Romero TR; Galdino GS; Silva GC; Resende LC; Perez AC; Cortes SF; Duarte ID
J Neurosci Res; 2012 Jul; 90(7):1474-9. PubMed ID: 22411529
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the anti-inflammatory potential of palmitoylethanolamide.
Alhouayek M; Muccioli GG
Drug Discov Today; 2014 Oct; 19(10):1632-9. PubMed ID: 24952959
[TBL] [Abstract][Full Text] [Related]
17. Palmitoylethanolamide in CNS health and disease.
Mattace Raso G; Russo R; Calignano A; Meli R
Pharmacol Res; 2014 Aug; 86():32-41. PubMed ID: 24844438
[TBL] [Abstract][Full Text] [Related]
18. Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice.
Di Paola R; Impellizzeri D; Mondello P; Velardi E; Aloisi C; Cappellani A; Esposito E; Cuzzocrea S
Shock; 2012 Oct; 38(4):356-66. PubMed ID: 22772472
[TBL] [Abstract][Full Text] [Related]
19. Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis.
Vaia M; Petrosino S; De Filippis D; Negro L; Guarino A; Carnuccio R; Di Marzo V; Iuvone T
Eur J Pharmacol; 2016 Nov; 791():669-674. PubMed ID: 27720681
[TBL] [Abstract][Full Text] [Related]
20. N-palmitoylethanolamide in the anterior cingulate cortex attenuates inflammatory pain behaviour indirectly via a CB1 receptor-mediated mechanism.
Okine BN; Madasu MK; McGowan F; Prendergast C; Gaspar JC; Harhen B; Roche M; Finn DP
Pain; 2016 Dec; 157(12):2687-2696. PubMed ID: 27649266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
